natgillin/translations-raw huggingface dataset:
If you are pregnant or breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku za savjet prije nego uzmete ovaj lijek.
If you notice any of these symptoms seek medical advice immediately;
Ako primijetite bilo koji od ovih simptoma, odmah zatražite liječnički savjet;
Date of latest renewal: 19 August 2014
Datum posljednje obnove: 19 Kolovoz 2014
Gröbenzell, Germany
Gröbenzell, Njemačka
City Tower, Hvězdova 1716/2b, 140 78 Praha 4 Czech Republic
City Tower, Hvězdova 1716/2b, 140 78 Praha 4 Češka Republika
- if you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).
• Ako od ranije imate dijagnosticirane tegobe s očima kao što su određene vrste glaukoma (povišeni očni tlak).
Your doctor will tell you how many Olanzapine Glenmark tablets to take and how long you should continue to take them.
Liječnik će Vam reći koliko Olanzapine Glenmark tableta trebate uzeti i koliko ćete ih dugo nastaviti uzimati.
Hertfordshire, WD18 8YA, United Kingdom
Hertfordshire, WD18 8YA, Velika Britanija
28 tablets 35 tablets 56 tablets 70 tablets 98 tablets
28 tableta 35 tableta 56 tableta 70 tableta 98 tableta
- Medicines of this type may cause unusual movements mainly of the face or tongue.
• Lijekovi ove vrste mogu uzrokovati pojavu neuobičajenih pokreta, uglavnom lica ili jezika.
16 Elevated plasma prolactin levels were reported in 47.4 % of adolescent patients.
16 Povišene razine prolaktina u plazmi prijavljene su u 47,4% adolescentnih bolesnika.
Date of first authorisation: 03 December 2009 Date of latest renewal: 19 August 2014
Datum prvog odobrenja: 03 Prosinac 2009 Datum posljednje obnove: 19 Kolovoz 2014
In clinical studies, the average olanzapine exposure was approximately 27 % higher in adolescents.
U kliničkim ispitivanjima prosječna izloženost olanzapinu bila je približno 27% viša u adolescenata.
Store below 30C.
Čuvati na temperaturi ispod 30°C.
Olanzapine is metabolized in the liver by conjugative and oxidative pathways.
Olanzapin se metabolizira u jetri konjugacijskim i oksidacijskim putevima.
• unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue;
• neuobičajene pokrete (česta nuspojava koja se može pojaviti u do 1 na 10 osoba) uglavnom na licu ili jeziku;
Keep this medicine out of sight and reach of children
Ovaj lijek čuvajte izvan pogleda i dohvata djece.
However, olanzapine (5-20 mg) demonstrated a comparable safety profile in female (n = 467) as in male patients (n = 869).
Međutim, olanzapin (5-20 mg) je u bolesnica (n=467) pokazao profil sigurnosti usporediv s onim u bolesnika (n=869).
However, the magnitude of the impact of age, gender, or smoking on olanzapine clearance and half-life is small in comparison to the overall variability between individuals.
Međutim, veličina utjecaja dobi, spola ili pušenja na klirens i poluvijek olanzapina malena je u usporedbi s ukupnom varijabilnošću među pojedincima.
Olanzapine was not mutagenic or clastogenic in a full range of standard tests, which included bacterial mutation tests and in vitro and in vivo mammalian tests.
Olanzapin nije bio mutagen ni klastogen u punom rasponu standardnih testova koji su uključivali testove bakterijske mutacije te in vitro i in vivo testove na sisavcima.
Very common: Sedation (including: hypersomnia, lethargy, somnolence).
Vrlo često: sedacija (uključujući: hipersomniju, letargiju, somnolenciju).
Carcinogenicity Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.
Na temelju rezultata ispitivanja u miševa i štakora zaključeno je da olanzapin nije kancerogen.
Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60 % and should be taken at least 2 hours before or after olanzapine.
Aktivni ugljen smanjuje bioraspoloživost oralnog olanzapina za 50 do 60% te ga treba uzeti najmanje 2 sata prije ili poslije olanzapina.
In 44 patients with schizophrenia > 65 years of age, dosing from 5 to 20 mg/day was not associated with any distinguishing profile of adverse events.
U 44 bolesnika sa shizofrenijom u dobi iznad 65 godina doziranje od 5 do 20 mg/dan nije bilo povezano ni sa kakvim posebnim profilom nuspojava.
The higher incidence of death was not associated with olanzapine dose (mean daily dose 4.4 mg) or duration of treatment.
Veća incidencija smrtnosti nije bila povezana s dozom olanzapina (srednja vrijednost dnevne doze od 4,4 mg) ni trajanjem liječenja.
In patients with Parkinson's disease Olanzapine Glenmark may worsen the symptoms.
U bolesnika koji boluju od Parkinsonove bolesti, Olanzapine Glenmark može pogoršati simptome.
Olanzapine is bound predominantly to albumin and α1-acid-glycoprotein.
Olanzapin se prvenstveno veže za albumin i α1-kiseli-glikoprotein.
1 Clinically significant weight gain was observed across all baseline Body Mass Index (BMI)
1 Klinički značajno povećanje tjelesne težine uočeno je u svim početnim kategorijama indeksa tjelesne mase (BMI).
Very common: Weight gain 13, elevated triglyceride levels 14, increased appetite.
Vrlo često: povećanje tjelesne težine13, povišene razine triglicerida14, povećan apetit.
Fatal outcomes have been reported for acute overdoses as low as 450 mg but survival has also been reported following acute overdose of approximately 2 g of oral olanzapine.
Prijavljeni su smrtni ishodi kod akutnog predoziranja već pri maloj dozi od 450 mg, ali je opisano i preživljavanje nakon akutnog predoziranja s približno 2 g oralnog olanzapina.
Children and adolescents Olanzapine Glenmark is not for patients who are under 18 years.
Djeca i adolescenti Olanzapine Glenmark nije za primjenu u bolesnika mlađih od 18 godina.
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
Detaljnije informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu.
What Olanzapine Glenmark is and what it is used for
Što je Olanzapin Glenmark i za što se koristi
If you forget to take Olanzapine Glenmark Take your tablets as soon as you remember.
Ako ste zaboravili uzeti lijek Olanzapine Glenmark Uzmite tablete čim se sjetite.
Clinically significant weight gain (≥ 7 %) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
Čini se da se klinički značajno povećanje tjelesne težine (≥ 7%) češće javlja u populaciji adolescenata u usporedbi s odraslim osobama s usporedivim izlaganjima lijeku.
A lower starting dose (5 mg/day) is not routinely indicated but should be considered for those 65 and over when clinical factors warrant (see section 4.4).
Niža početna doza (5 mg/dan) nije rutinski indicirana, no treba je razmotriti u osoba u dobi od 65 ili više godina, kada to opravdavaju klinički čimbenici (vidjeti dio 4.4).
Patients should be advised not to breast- feed an infant if they are taking olanzapine.
Bolesnice treba savjetovati da ne doje dijete ako uzimaju olanzapin.
What Olanzapine Glenmark is and what it is used for What you need to know before you take Olanzapine Glenmark How to take Olanzapine Glenmark Possible side effects
Što je Olanzapin Glenmark i za što se koristi Što morate znati prije nego počnete uzimati Olanzapin Glenmark Kako uzimati Olanzapin Glenmark Moguće nuspojave
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS Aluminium blisters
PODACI KOJE MORA NAJMANJE SADRŽAVATI BLISTER ILI STRIP Aluminijski blisteri
You should take your Olanzapine Glenmark tablets once a day following the advice of your doctor.
Olanzapine Glenmark tablete morate uzimati jednom dnevno pridržavajući se savjeta svog liječnika.
A mass balance study showed that approximately 57 % of radiolabelled olanzapine appeared in urine, principally as metabolites.
Ispitivanje masene bilance pokazalo je da se približno 57% olanzapina označenog radioizotopom pojavljuje u mokraći, uglavnom u obliku metabolita.
You should not be given this medicine when breast-feeding, as small amounts of Olanzapine Glenmark can pass into breast milk.
Ne biste smjeli uzimati ovaj lijek dok dojite, jer se male količine lijeka Olanzapine Glenmark mogu izlučiti u majčino mlijeko.
Do not use epinephrine, dopamine, or other sympathomimetic agents with beta-agonist activity since beta stimulation may worsen hypotension.
Ne koristite epinefrin, dopamin ili druge simpatomimetike s beta-agonističkim djelovanjem jer beta stimulacija može pogoršati hipotenziju.
How to store Olanzapine Glenmark Contents of the pack and other information
Kako čuvati Olanzapin Glenmark Sadržaj pakiranja i druge informacije
• Carbamazepine (an anti-epileptic and mood stabiliser), fluvoxamine (an antidepresant) or ciprofloxacin (an antibiotic) - it may be necessary to change your Olanzapine Glenmark dose.
• karbamazepin (antiepileptik i stabilizator raspoloženja), fluvoksamin (antidepresiv) ili ciprofloksacin (antibiotik) - možda će biti potrebno promijeniti dozu lijeka Olanzapine
If you take more Olanzapine Glenmark than you should Patients who have taken more Olanzapine Glenmark than they should have experienced the following symptoms: rapid beating of the heart, agitation/aggressiveness, problems with speech, unusual movements (especially of the face or tongue) and reduced level of consciousness.
Ako uzmete više lijeka Olanzapine Glenmark nego što ste trebali Bolesnici koji su uzeli više lijeka Olanzapine Glenmark nego što su trebali imaju sljedeće simptome: ubrzan rad srca, uznemirenost/agresivnost, poteškoće s govorom, neuobičajene pokrete (osobito lica ili jezika) i sniženu razinu svijesti.
The magnitude of weight gain and the proportion of adolescent patients who had clinically significant weight gain were greater with long-term exposure (at least 24 weeks) than with short-term exposure.
Povećanje tjelesne težine i udio adolescentnih bolesnika koji su imali klinički značajno povećanje tjelesne težine bili su veći tijekom dugotrajnog izlaganja (najmanje 24 tjedana) nego tijekom kratkotrajnog izlaganja lijeku.
• blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
• krvne ugruške u venama (manje česta nuspojava koja se može pojaviti u do 1 na 100 osoba), posebno u nogama (simptomi uključuju oticanje, bol i crvenilo nogu), koji mogu putovati krvnim žilama do pluća, uzrokujući bol u prsima i otežano disanje.
Common: Elevated cholesterol levels 15
Često: povišene razine kolesterola15
However the risk of tardive dyskinesia increases with long-term exposure, and therefore if signs or symptoms of tardive dyskinesia appear in a patient on olanzapine, a dose reduction or discontinuation should be considered.
Međutim, rizik od tardivne diskinezije povećava se s dugotrajnom izloženošću te u slučaju pojave znakova ili simptoma tardivne diskinezije u bolesnika na olanzapinu treba razmotriti snižavanje doze ili prekid liječenja.
Mean infant exposure (mg/kg) at steady state was estimated to be 1.8 % of the maternal olanzapine dose (mg/kg).
Srednja vrijednost izloženosti novorođenčeta (mg/kg) u stanju dinamičke ravnoteže procijenjena je na 1,8% majčine doze olanzapina (mg/kg).
Very common: Decreased total bilirubin, increased GGT, elevated plasma prolactin levels 16
Vrlo često: smanjenje ukupnog bilirubina, povećan GGT, povišene razine prolaktina u plazmi16.
• If you know that you may have salt depletion as a result of prolonged severe diarrhoea and vomiting (being sick) or usage of diuretics (water tablets)
• ako znate da možda imate nedovoljno soli u organizmu kao posljedicu dugotrajnog teškog proljeva i povraćanja ili zbog uzimanja diuretika (tableta za izlučivanje vode iz organizma)
Olanzapine Glenmark 2.5 mg tablets Olanzapine Glenmark 5 mg tablets Olanzapine Glenmark 7.5 mg tablets Olanzapine Glenmark 10 mg tablets Olanzapine Glenmark 15 mg tablets Olanzapine Glenmark 20 mg tablets
Olanzapin Glenmark 2,5 mg tablete Olanzapin Glenmark 5 mg tablete Olanzapin Glenmark 7,5 mg tablete Olanzapin Glenmark 10 mg tablete Olanzapin Glenmark 15 mg tablete Olanzapin Glenmark 20 mg tablete olanzapin
Ventricular tachycardia/fibrillation, sudden death (see section 4.4)11
ventrikularna tahikardija/ fibrilacija, iznenadna smrt (vidjeti dio 4.4)11
It is important that you carry on taking Olanzapine Glenmark for as long as your doctor tells you.
Važno je da nastavite uzimati lijek Olanzapine Glenmark onoliko dugo koliko Vam je liječnik rekao.
However, the incidence of death was higher in olanzapine-treated than in placebo-treated patients independent of these risk factors.
Međutim, incidencija smrtnosti bila je veća u bolesnika liječenih olanzapinom nego u bolesnika koji su primali placebo, neovisno o ovim čimbenicima rizika.
Consult your doctor if your symptoms return but do not stop taking Olanzapine Glenmark unless your doctor tells you to.
Ako Vam se simptomi vrate, posavjetujte se sa svojim liječnikom, ali nemojte prestati uzimati lijek Olanzapine Glenmark dok Vam liječnik to ne kaže.
The following symptoms may occur in newborn babies, of mothers that have used Olanzapine Glenmark in the last trimester (last three months of their pregnancy): shaking, muscle stiffness and/or weakness, sleepiness, agitation, breathing problems, and difficulty in feeding.
Sljedeći simptomi mogu se pojaviti u novorođenčadi majki koje su koristile lijek Olanzapine Glenmark u posljednjem tromjesečju (zadnja tri mjeseca trudnoće): drhtanje, ukočenost mišića i/ili slabost, pospanost, uznemirenost, tegobe s disanjem te poteškoće u hranjenju.
Controlled efficacy data in adolescents (ages 13 to 17 years) are limited to short term studies in schizophrenia (6 weeks) and mania associated with bipolar I disorder (3 weeks), involving less than 200 adolescents.
Podaci o djelotvornosti iz kontroliranih ispitivanja u adolescenata (u dobi od 13 do 17 godina) su ograničeni na kratkotrajna ispitivanja u shizofreniji (6 tjedana) i maniji povezanima s bipolarnim poremećajem I (3 tjedna), a obuhvatilo je manje od 200 adolescenata.
Olanzapine administered with lithium or valproate resulted in increased levels (≥ 10 %) of tremor, dry mouth, increased appetite, and weight gain.
Olanzapin primijenjen s litijem ili valproatom rezultirao je povećanim razinama ( 10%) tremora, suhoće usta, povećanjem apetita i povećanjem tjelesne težine.
The plasma protein binding of olanzapine was about 93 % over the concentration range of about 7 to about 1000 ng/ml.
Vezanje olanzapina na proteine u plazmi bilo je oko 93% u rasponu koncentracija od približno 7 do približno 1000 ng/ml.
In a retrospective observational cohort study, the risk of presumed sudden cardiac death in patients treated with olanzapine was approximately twice the risk in patients not using antipsychotics.
U retrospektivnom opservacijskom kohortnom ispitivanju rizik od pretpostavljene iznenadne srčane smrti u bolesnika liječenih olanzapinom bio je otprilike dvostruko veći nego u bolesnika koji nisu uzimali antipsihotike.
• Medicines for Parkinson's disease
• lijekove protiv Parkinsonove bolesti
The mean increase in olanzapine Cmax following fluvoxamine was 54 % in female non smokers and 77 % in male smokers.
Srednja vrijednost porasta Cmax olanzapina nakon primjene fluvoksamina iznosio je 54% u žena nepušača i 77% u muškaraca pušača.
• In the early stages of treatment, some people may feel dizzy or faint (with a slow heart rate), especially when getting up from a lying or sitting position.
U ranim fazama liječenja neki bolesnici mogu osjećati omaglicu ili nesvjesticu (uz usporen rad srca), posebno pri uspravljanju iz ležećeg ili sjedećeg položaja tijela.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
U istim kliničkim ispitivanjima prijavljeni su cerebrovaskularni štetni događaji (CV štetni događaji, primjerice moždani udar, prolazni ishemijski napad), uključujući smrtne slučajeve.
Given the primary CNS effects of olanzapine, caution should be used when it is taken in combination with other centrally acting medicines and alcohol.
S obzirom na primarne učinke olanzapina na središnji živčani sustav, oprez je potreban kod njegove primjene u kombinaciji s drugim centralno djelujućim lijekovima i alkoholom.
The daily dose of Olanzapine Glenmark is between 5 mg and 20 mg.
Dnevna doza lijeka Olanzapine Glenmark iznosi između 5 mg i 20 mg.
Olanzapine was used as a flexible dose starting with 2.5 and ranging up to 20 mg/day.
Olanzapin se primjenjivao u fleksibilnoj dozi koja je započinjala s 2,5 mg dnevno i postupno je povećavana do 20 mg dnevno.
The most frequently (seen in ≥ 1 % of patients) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najčešće prijavljene nuspojave (uočene u ≥ 1% bolesnika) povezane s primjenom olanzapina u kliničkim ispitivanjima bile su somnolencija, povećanje tjelesne težine, eozinofilija, povišene vrijednosti prolaktina, kolesterola, glukoze i triglicerida (vidjeti dio 4.4), glikozurija, povećan apetit, omaglica, akatizija, parkinsonizam, leukopenija, neutropenija (vidjeti dio 4.4), diskinezija, ortostatska hipotenzija, antikolinergički učinci, prolazni asimptomatski porasti vrijednosti jetrenih aminotransferaza (vidjeti dio 4.4), osip, astenija, umor, pireksija, artralgija, povišena razina alkalne fosfataze, visoka razina gama glutamiltransferaze, visoka razina mokraćne kiseline, visoka razina kreatin fosfokinaze i edem.
The concomitant administration of activated charcoal was shown to reduce the oral bioavailability of olanzapine by 50 to 60 %.
Pokazalo se da istodobna primjena aktivnog ugljena smanjuje oralnu bioraspoloživost olanzapina za 50 do 60%.
During treatment for schizophrenia, manic episode and recurrence prevention in bipolar disorder, daily dosage may subsequently be adjusted on the basis of individual clinical status within the range 520 mg/day.
Tijekom liječenja shizofrenije, epizode manije te prevencije relapsa bipolarnog poremećaja, dnevna doza se može naknadno podesiti na temelju kliničke slike pojedinog bolesnika u rasponu od 5 do 20 mg/dan.
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 < 1/100), rare (≥ 1/10,000 to< 1/1,000), very rare (< 1/10,000), not known (cannot be estimated from the data available).
Učestalost je definirana kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10), manje često (≥ 1/1000 i < 1/100), rijetko (≥ 1/10 000 i < 1/1000), vrlo rijetko (< 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
The frequency terms listed are defined as follows: Very common (≥ 1/10), common (≥ 1/100 to <
Navedene učestalosti definirane su kako slijedi: vrlo često (≥ 1/10), često (≥ 1/100 i < 1/10).
Standard procedures for management of overdose may be indicated (i.e. gastric lavage, administration of activated charcoal).
Mogu biti indicirani standardni postupci za liječenje predoziranja (tj. ispiranje želuca, primjena aktivnog ugljena).
Warnings and precautions Talk to your doctor or pharmacist before you take Olanzapine Glenmark
Obratite se svom liječniku ili ljekarniku prije nego uzmete lijek Olanzapine Glenmark.
Crospovidone Magnesium stearate
krospovidon magnezijev stearat
During treatment with olanzapine in combination with lithium or divalproex, an increase of ≥ 7 % from baseline body weight occurred in 17.4 % of patients during acute treatment (up to 6 weeks).
Tijekom liječenja olanzapinom u kombinaciji s litijem ili divalproeksom, porast tjelesne težine  7% od početne pojavio se u 17,4% bolesnika tijekom akutnog liječenja (do 6 tjedana).
However, as clinical experience with olanzapine in patients with concomitant illness is limited, caution is advised when prescribing for patients with prostatic hypertrophy, or paralytic ileus and related conditions.
Međutim, kako je kliničko iskustvo s olanzapinom u bolesnika s konkomitantnom bolešću ograničeno, savjetuje se oprez pri propisivanju lijeka bolesnicima s hipertrofijom prostate ili paralitičkim ileusom i povezanim stanjima.
Cytochromes P450-CYP1A2 and P450-CYP2D6 contribute to the formation of the N-desmethyl and 2-hydroxymethyl metabolites, both exhibited significantly less in vivo pharmacological activity than olanzapine in animal studies.
Citokromi P450-CYP1A2 i P450-CYP2D6 doprinose stvaranju N-dezmetil i 2-hidroksimetil metabolita te u ispitivanjima na životinjama oba pokazuju značajno manje in vivo farmakološko djelovanje od olanzapina.
Do not stop taking your tablets just because you feel better.
Ako prestanete uzimati lijek Olanzapine Glenmark Nemojte prestati uzimati tablete samo zato jer se osjećate bolje.
Olanzapine should be used cautiously in patients who have a history of seizures or are subject to factors, which may lower the seizure threshold.
Olanzapin treba oprezno primjenjivati u bolesnika imaju napadaje u anamnezi ili su izloženi čimbenicima koji mogu sniziti prag za napadaje.
Undesirable alterations in lipids have been observed in olanzapine-treated patients in placebocontrolled clinical trials (see section 4.8).
Neželjene promjene vrijednosti lipida uočene su u bolesnika liječenih olanzapinom u placebom kontroliranim kliničkim ispitivanjima (vidjeti dio 4.8).
Long-term olanzapine treatment (up to 12 months) for recurrence prevention in patients with bipolar disorder was associated with an increase of ≥ 7 % from baseline body weight in 39.9 % of patients.
Dugotrajno liječenje olanzapinom (do 12 mjeseci) radi prevencije relapsa u bolesnika s bipolarnim poremećajem bilo je povezano s povećanjem tjelesne težine  7% od početne tjelesne težine u 39,9% bolesnika.
Very common symptoms in overdose (> 10 % incidence) include tachycardia, agitation/ aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
Vrlo česti simptomi predoziranja (incidencija > 10%) obuhvaćaju tahikardiju, agitaciju/agresivnost, dizartriju, različite ekstrapiramidalne simptome te smanjenu razinu svijesti u rasponu od sedacije do kome.
8 In clinical trials of up to 12 weeks, plasma prolactin concentrations exceeded the upper limit of normal range in approximately 30% of olanzapine treated patients with normal baseline prolactin value.
8 U kliničkim ispitivanjima u trajanju do 12 tjedana koncentracije prolaktina u plazmi prelazile su gornju granicu normalnog raspona u približno 30% bolesnika liječenih olanzapinom s normalnom početnom vrijednošću prolaktina.
Reversible neutropenia, thrombocytopenia, or anaemia developed in a few dogs treated with 8 or 10 mg/kg/day (total olanzapine exposure [AUC] is 12- to 15-fold greater than that of a man given a 12-mg dose).
Reverzibilna neutropenija, trombocitopenija ili anemija razvile su se u malog broja pasa liječenih dozom od 8 ili 10 mg/kg/dan (ukupna izloženost olanzapinu [AUC] je 12 do 15 puta veća nego izloženost u čovjeka kojemu je dana doza od 12 mg).
In the study, the risk of olanzapine was comparable to the risk of atypical antipsychotics included in a pooled analysis.
U ispitivanju je rizik povezan s olanzapinom bio usporediv s rizikom povezanim s atipičnim antipsihoticima uključenima u objedinjenu analizu.